Ad.26.COV2.S(Janssen[强生])疫苗基础免疫后同源与异源COVID-19加强针针对COVID-19相关急诊及紧急护理就诊和住院的有效性——VISION网络,10个州,2021年12月至2022年3月
CDC建议≥18岁人群在接种Ad.26.COV2.S(Janssen[强生])腺病毒载体基础免疫疫苗≥2个月后接种单剂COVID-19疫苗加强针,异源mRNA疫苗优先于同源Janssen疫苗。VISION网络在2021年12月16日至2022年3月7日Omicron变异株占优势期间分析10个州80,287次急诊/紧急护理就诊和25,244例住院,评估不同加强策略的真实世界疫苗有效性(VE)。
要点
- 针对急诊/紧急护理就诊的VE:1剂Janssen为24%,2剂Janssen为54%,1剂Janssen/1剂mRNA为79%,3剂mRNA为83%。
- 针对住院的VE:1剂Janssen为31%,2剂Janssen为67%,1剂Janssen/1剂mRNA为78%,3剂mRNA为90%。
- 所有加强策略的保护均高于单剂Janssen;1剂Janssen/1剂mRNA高于2剂Janssen,在加强后120天内与3剂mRNA相当。
核心结论
- 在Omicron变异株占优势期间,所有加强策略对急诊/紧急护理就诊和住院的保护均高于单剂Janssen疫苗。
- 1剂Janssen/1剂mRNA对急诊/紧急护理就诊的保护高于2剂Janssen,且在加强后120天内与3剂mRNA相当。
- 在加强后同一时间间隔内,3剂mRNA对COVID-19相关住院的保护高于其他加强策略。
- 所有以mRNA疫苗完成COVID-19基础免疫的成人符合条件时应接种mRNA加强针。
- 接种Janssen基础免疫的成人应优先在≥2个月后接种异源mRNA疫苗加强针;若mRNA疫苗禁忌或不可及,则接种同源Janssen疫苗加强针。
研究设计与样本
- VISION网络在10个州开展的真实世界疫苗有效性分析,时间为2021年12月16日至2022年3月7日,当时Omicron为主要流行变异株。
- 分析对象为80,287次急诊/紧急护理(ED/UC)就诊和25,244例住院。
- 比较1剂Janssen疫苗与两种加强策略:同源加强(2剂Janssen)和异源mRNA加强(1剂Janssen/1剂mRNA)。
- 并将上述加强策略与mRNA基础免疫后同源加强(3剂mRNA)的VE进行比较。
主要发现
- 针对实验室确诊COVID-19相关ED/UC就诊的VE:1剂Janssen为24%,2剂Janssen为54%,1剂Janssen/1剂mRNA为79%,3剂mRNA为83%。
- 针对实验室确诊COVID-19相关住院的VE:1剂Janssen为31%,2剂Janssen为67%,1剂Janssen/1剂mRNA为78%,3剂mRNA为90%。
- 1剂Janssen/1剂mRNA对COVID-19相关ED/UC就诊的保护高于2剂Janssen,且在加强后120天内与3剂mRNA相当。
- 在加强后同一时间间隔内,3剂mRNA对COVID-19相关住院的保护高于其他加强策略。
关键数值与推荐
- CDC建议所有≥18岁人群在接种Ad.26.COV2.S(Janssen[强生])腺病毒载体基础免疫疫苗后≥2个月接种单剂COVID-19疫苗加强针。
- 加强接种时,异源COVID-19 mRNA疫苗优先于同源(匹配)Janssen疫苗。
- 接种Janssen基础免疫的成人应优先在≥2个月后接种异源mRNA疫苗加强针,若mRNA疫苗禁忌或不可及则接种同源Janssen疫苗加强针。
- 所有以mRNA疫苗完成COVID-19基础免疫的成人符合条件时应接种mRNA加强针。
临床怎么用
- 作者指出,所有以mRNA疫苗完成基础免疫的成人符合条件时应接种mRNA加强针。
- 作者指出,接种Janssen基础免疫的成人应优先在≥2个月后接种异源mRNA疫苗加强针,若mRNA疫苗禁忌或不可及则接种同源Janssen疫苗加强针。
- CDC建议≥18岁人群在接种Janssen基础免疫疫苗≥2个月后接种单剂COVID-19疫苗加强针,并优先选择异源mRNA疫苗。
局限性
- 原文指出,关于Janssen基础免疫后不同加强策略真实世界VE的数据有限,尤其在Omicron变异株占优势期间。
- 原文结论提出,有必要进一步研究不同加强策略所提供保护的持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CDC recommends that all persons aged ≥18 years receive a single COVID-19 vaccine booster dose ≥2 months after receipt of an Ad.26.COV2.S (Janssen [Johnson & Johnson]) adenovirus vector-based primary series vaccine; a heterologous COVID-19 mRNA vaccine is preferred over a homologous (matching) Janssen vaccine for booster vaccination. This recommendation was made in light of the risks for rare but serious adverse events following receipt of a Janssen vaccine, including thrombosis with thrombocytopenia syndrome and Guillain-Barré syndrome† (1), and clinical trial data indicating similar or higher neutralizing antibody response following heterologous boosting compared with homologous boosting (2). Data on real-world vaccine effectiveness (VE) of different booster strategies following a primary Janssen vaccine dose are limited, particularly during the period of Omicron variant predominance. The VISION Network§ determined real-world VE of 1 Janssen vaccine dose and 2 alternative booster dose strategies: 1) a homologous booster (i.e., 2 Janssen doses) and 2) a heterologous mRNA booster (i.e., 1 Janssen dose/1 mRNA dose). In addition, VE of these booster strategies was compared with VE of a homologous booster following mRNA primary series vaccination (i.e., 3 mRNA doses). The study examined 80,287 emergency department/urgent care (ED/UC) visits¶ and 25,244 hospitalizations across 10 states during December 16, 2021-March 7, 2022, when Omicron was the predominant circulating variant.** VE against laboratory-confirmed COVID-19-associated ED/UC encounters was 24% after 1 Janssen dose, 54% after 2 Janssen doses, 79% after 1 Janssen/1 mRNA dose, and 83% after 3 mRNA doses. VE for the same vaccination strategies against laboratory-confirmed COVID-19-associated hospitalizations were 31%, 67%, 78%, and 90%, respectively. All booster strategies provided higher protection than a single Janssen dose against ED/UC visits and hospitalizations during Omicron variant predominance. Vaccination with 1 Janssen/1 mRNA dose provided higher protection than did 2 Janssen doses against COVID-19-associated ED/UC visits and was comparable to protection provided by 3 mRNA doses during the first 120 days after a booster dose. However, 3 mRNA doses provided higher protection against COVID-19-associated hospitalizations than did other booster strategies during the same time interval since booster dose. All adults who have received mRNA vaccines for their COVID-19 primary series vaccination should receive an mRNA booster dose when eligible. Adults who received a primary Janssen vaccine dose should preferentially receive a heterologous mRNA vaccine booster dose ≥2 months later, or a homologous Janssen vaccine booster dose if mRNA vaccine is contraindicated or unavailable. Further investigation of the durability of protection afforded by different booster strategies is warranted.
引用
- Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35358170. doi:10.15585/mmwr.mm7113e2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。